Showing 1 to 3 of 3 results


EU Approves Twice-Yearly HIV Prevention Injection
The European Commission approved Lenacapavir (Yeytuo), a twice-yearly HIV prevention injection, following a positive EMA recommendation and successful clinical trials showing 100% effectiveness; this comes amidst a rise in HIV cases in the EU and global efforts to combat the disease.
EU Approves Twice-Yearly HIV Prevention Injection
The European Commission approved Lenacapavir (Yeytuo), a twice-yearly HIV prevention injection, following a positive EMA recommendation and successful clinical trials showing 100% effectiveness; this comes amidst a rise in HIV cases in the EU and global efforts to combat the disease.
Progress
48% Bias Score


Annual HIV-Prevention Injection Shows Promise in Phase 1 Trial
A phase 1 trial showed a single intramuscular injection of lenacapavir provided effective HIV prevention for at least 56 weeks in 40 participants, potentially revolutionizing PrEP access and adherence, with a semiannual version under regulatory review.
Annual HIV-Prevention Injection Shows Promise in Phase 1 Trial
A phase 1 trial showed a single intramuscular injection of lenacapavir provided effective HIV prevention for at least 56 weeks in 40 participants, potentially revolutionizing PrEP access and adherence, with a semiannual version under regulatory review.
Progress
44% Bias Score

EU Approves Twice-Yearly HIV Prevention Injection
European regulators approved Gilead's lenacapavir, a twice-yearly HIV prevention injection, 100% effective in trials, offering a significant advancement amid rising HIV cases (24,700 new diagnoses in 2023, up 11.8% from 2022).

EU Approves Twice-Yearly HIV Prevention Injection
European regulators approved Gilead's lenacapavir, a twice-yearly HIV prevention injection, 100% effective in trials, offering a significant advancement amid rising HIV cases (24,700 new diagnoses in 2023, up 11.8% from 2022).
Progress
40% Bias Score
Showing 1 to 3 of 3 results